Institutional Ownership Xtl Biopharmaceuticals LTD (XTLB)
This table provides information about the institutional ownership of Xtl Biopharmaceuticals LTD (XTLB). We have compiled data on the 5 institutions that hold shares in the stock, with a total of 427,081 shares, which have been reported (via 13F filing form) to have a value of $486,000.
Holding | Report Date | shares Held | Holding Value (Reported) | Last Trade | Trade History |
---|---|---|---|---|---|
Noked Capital LTD
Tel Aviv, L3 |
Nov 14, 2022 Q3 2022 |
198,888
shares
|
$226,732
0.02% of portfolio
|
Q3 2019
Reduced -0.0%
|
|
Noked Israel LTD
Ramat Hasharon, L3 |
Feb 14, 2025 Q4 2024 |
198,888
shares
|
$226,732
0.08% of portfolio
|
Q3 2019
Reduced -0.0%
|
|
Morgan Stanley
New York, NY |
Feb 14, 2025 Q4 2024 |
18,351
shares
|
$20,920
0.0% of portfolio
|
Q4 2024
Reduced 30.62%
|
|
Rhumbline Advisers
Boston, MA |
Jan 30, 2025 Q4 2024 |
10,954
shares
|
$12,487
0.0% of portfolio
|
Q4 2024
Added 68.03%
|
|
Concourse Financial Group Securities, Inc.
Birmingham, AL |
Feb 13, 2025 Q4 2024 |
0
shares
|
$0
0.0% of portfolio
|
Q4 2024
New holding
|